Jakob Madsen

Medicine and Dentistry

1. Patient 100%
2. Diffuse Large B-Cell Lymphoma 81%
3. Lymphoma 50%
4. Cohort Analysis 44%
5. Therapeutic Procedure 37%
6. Inpatient 33%
7. Chemotherapy 29%
8. Peripheral T-Cell Lymphoma 28%
9. Gene 22%
10. Diagnosis 21%
11. Multiple Myeloma 21%
12. Clinical Trial 19%
13. Malignant Neoplasm 17%
14. Evaluation Study 16%
15. B Cell 15%
16. Hospital 15%
17. Proportional Hazards Model 15%
18. Analysis 15%
19. Incidence 14%
20. Hemoglobin 14%
21. Venous Thromboembolism 14%
22. Thymus 14%
23. Work Disability 14%
24. Agents Acting on the Eye 14%
25. Personalized Medicine 14%
26. Cancer Cell Line 14%
27. Development 14%
28. Neutrophil 14%
29. Memory B Cell 14%
30. Hematological Cancer 14%
31. Drug Effect 14%
32. Anthracycline 14%
33. PET-CT 14%
34. Socioeconomic Status 14%
35. Neutropenia 14%
36. Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine 14%
37. Age 13%
38. Infection 11%
39. Diseases 10%
40. Drug Resistance 9%
41. Anaplastic Lymphoma Kinase 9%
42. Acute Myeloid Leukemia 8%
43. Hazard Ratio 8%
44. Comorbidity 8%
45. MALT Lymphoma 8%
46. Neoplasm 7%
47. Disability Pension 6%
48. Death 5%
49. T-Cell Lymphoma 5%
50. International Prognostic Index 5%